Phase 4
N=31
Lipids of the Human Tear Film and Their Effect on Tear Stability
Blepharitis
Bottom Line
View on ClinicalTrials.gov: NCT00803452 ↗Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcome: Primary: Global Response to Therapy — 16; 41 eyes — p=.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- doxycycline (Drug); azithromycin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Louisville
- Primary completion
- Dec 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Global Response to Therapy |
16; 41 | .001 sig |
Summary
This prospective, randomized, comparative clinical trial evaluates the effect of either oral doxycycline, oral essential fatty acid, or topical azithromycin to modify the secretions of the meibomian gland in subjects with meibomian gland dysfunction and/or dry eye disease.
Eligibility Criteria
Inclusion Criteria
- Meibomian gland dysfunction
Exclusion Criteria
- Lid margin scarring; herpetic blepharitis
Data sourced from ClinicalTrials.gov (NCT00803452). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.